Aptose Biosciences (APTO)
(Delayed Data from NSDQ)
$0.67 USD
-0.03 (-4.41%)
Updated Jul 16, 2024 03:59 PM ET
After-Market: $0.68 +0.01 (1.19%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Income Statements
Fiscal Year end for Aptose Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 52 | 43 | 65 | 56 | 27 |
Income After Depreciation & Amortization | -52 | -43 | -65 | -56 | -27 |
Non-Operating Income | 1 | 1 | 0 | 1 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -51 | -42 | -65 | -55 | -26 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -51 | -42 | -65 | -55 | -26 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -51 | -42 | -65 | -55 | -26 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -52 | -42 | -65 | -55 | -26 |
Depreciation & Amortization (Cash Flow) | 0 | 1 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -52 | -43 | -65 | -56 | -27 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 6.76 | 6.20 | 5.97 | 5.50 | 3.37 |
Diluted EPS Before Non-Recurring Items | -7.58 | -6.75 | -10.95 | -10.05 | -7.80 |
Diluted Net EPS (GAAP) | -7.58 | -6.75 | -10.94 | -10.04 | -7.80 |
Fiscal Year end for Aptose Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 9.77 | 12.13 | 11.69 | 14.45 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -9.77 | -12.13 | -11.69 | -14.45 |
Non-Operating Income | NA | 0.12 | 0.17 | 0.23 | 0.32 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -9.64 | -11.96 | -11.45 | -14.13 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -9.64 | -11.96 | -11.45 | -14.13 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -9.64 | -11.96 | -11.45 | -14.13 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 13.13 | 6.76 | 6.50 | 6.23 |
Diluted EPS Before Non-Recurring Items | NA | -0.73 | -1.44 | -1.76 | -2.27 |
Diluted Net EPS (GAAP) | NA | -0.73 | -1.30 | -1.76 | -2.27 |